Cildraw O Tablet combines Cilnidipine 10mg and Olmesartan 20mg, a dual-action antihypertensive formulation designed for optimal blood pressure management and cardiovascular protection. This combination helps relax blood vessels and reduce vascular resistance, providing effective therapy for hypertensive patients.
Cilnidipine, a calcium channel blocker, lowers peripheral resistance and improves cardiac output, while Olmesartan, an angiotensin receptor blocker, helps relax blood vessels and control blood pressure. Together, they provide comprehensive antihypertensive therapy with enhanced patient compliance.
This dual-combination tablet is widely prescribed for patients with essential hypertension, high cardiovascular risk, or vascular stiffness. Its balanced efficacy and tolerability make it a preferred therapy among cardiologists and general physicians.
Adding Olmeslide LN 20 Tablet to your cardiology and antihypertensive portfolio strengthens your product range with a clinically effective, high-demand combination. It offers opportunities for hospital supply, retail pharmacy distribution, institutional tenders, export markets, and third-party manufacturing, ensuring consistent market demand and profitability.